Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NovaBridge Biosciences

Request full access

Rockville-based global biotech platform (Nasdaq: NBP, formerly I-Mab) developing givastomig, a CLDN18.2 x 4-1BB bispecific for gastric cancer

Rockville, United StatesFounded 2016Biotech & Life Sciences

About NovaBridge Biosciences

NovaBridge Biosciences (Nasdaq: NBP), formerly I-Mab, is a Rockville, Maryland-based global biotechnology platform company focused on accelerating access to innovative medicines. Founded in 2016 in Shanghai by Dr. Jingwu Zang, the company divested its China operations in 2024, relocated to the US, and changed its name from I-Mab to NovaBridge Biosciences in October 2025, when its ADSs began trading under the ticker NBP. Its lead candidate, givastomig, is a Claudin 18.2 x 4-1BB bispecific antibody co-developed with ABL Bio for HER2-negative, CLDN18.2-positive gastric and gastroesophageal cancer; it entered a global randomized Phase 2 study in February 2026 and received FDA Fast Track designation in June 2026. The pipeline also includes VIS-101, a bifunctional VEGF-A/ANG2 inhibitor held by subsidiary Visara, the PD-L1 x 4-1BB bispecific ragistomig (with ABL Bio), and ex-China rights to the anti-CD73 antibody uliledlimab. CEO is Sean Fu, PhD.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020

NovaBridge Biosciences in the Rockville ecosystem

Live from Dealroom

The NovaBridge Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • CBC Group
  • Cambridge Capital
  • Genexine
  • Tasly Pharmaceutical

Series B and later15 investors entered at this stage

  • Hony Capital
  • CDH Investments
  • Hillhouse Capital
  • Ally Bridge Group
  • Tally Capital
  • EDBI
  • HOPU Fund
  • C-Bridge Capital
  • VMS Group
  • I-Mab
  • Bruggemoon
  • Tailong Investment
  • Kaitou Hanrun Capital
  • Qiantang Chengfa
  • Heda Investment
Team profiled 20 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$57M

57 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See NovaBridge Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.